Nifedipine gastrointestinal therapeutic system: an overview of its antiatherosclerotic effects

Bibliography

• SANZ J, MORENO PR, FUSTER V: The year in atherothrombosis. J. Am. Coll. Cardiol. (2007) 49(16):1740-1749.
   PubMed Web of Science ®Google Scholar
• FADINI GP, AGOSTINI C, SARTORE S, AVOGARO A: Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis (2007):(In Press).
   Google Scholar
• LIBBY P: Inflammation in atherosclerosis. Nature (2002) 420:868-874.
   PubMed Web of Science ®Google Scholar
• LIBBY P, RIDKER PM, MASERI A: Inflammation and atherosclerosis. Circulation (2002) 105:1135-1143.
   PubMed Web of Science ®Google Scholar
• HIRSCH EZ, CHISOLM GM III, WHITE HM: Reendothelialization and maintenance of endothelial integrity in longitudinal denuded tracks in the thoracic aorta of rats. Atherosclerosis (1983) 46:287-307.
   PubMed Web of Science ®Google Scholar
• ASAHARA T, MUROHARA T, SULLIVAN A et al.: Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 275:964-967.
   PubMed Web of Science ®Google Scholar
• REIDY MA, BOWYER DE: Distortion of endothelial repair. The effect of hypercholesterolaemia on regeneration of aortic endothelium following injury by endotoxin. A scanning electron microscope study. Atherosclerosis (1978) 29:459-466.
   PubMed Web of Science ®Google Scholar
• GALLO R, BADIMON JJ, FUSTER V: Pathobiology of coronary ischemic events: clinical implications. Adv. Int. Med. (1998) 43:203-232.
   PubMedGoogle Scholar
• JANOWITZ WR, AGATSTON AS, KAPLAN G et al.: Differences in prevalence and extent of coronary artery calcium detected by ultrafast computed tomography in asymptomatic men and women. Am. J. Cardiol. (1993) 72:247-254.
   PubMed Web of Science ®Google Scholar
• FRONTINI MG, SRINIVASAN SR, XU JH et al.: Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults (The Bogalusa heart study). Am. J. Cardiol. (2007) 100:64-68.
   PubMed Web of Science ®Google Scholar
• BERENSON GS, SRINIVASAN SR, BAO W: Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa heart study. N. Engl. J. Med. (1998) 338:1650-1656.
   PubMed Web of Science ®Google Scholar
• LI S, CHEN W, SRINIVASAN SR et al.: Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa heart study. JAMA (2003) 290:2271-2276.
   PubMed Web of Science ®Google Scholar
• BERENSON GS: Childhood risk factors predict adult risk associated with subclinical cardiovascular disease. The Bogalusa heart study. Am. J. Cardiol. (2002) 90:L3-L7.
   PubMed Web of Science ®Google Scholar
• PAUL TK, SRINIVASAN SR, BOND MG et al.: Cardiovascular risk profile of asymptomatic healthy young adults with increased femoral artery intima-media thickness: the Bogalusa heart study. Am. J. Med. Sci. (2005) 330:105-110.
   PubMed Web of Science ®Google Scholar
• STRONG JP, MALCOLM GT, MCMAHAN CA et al.: Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the pathobiological determinants of atherosclerosis in youth study. JAMA (1999) 281:727-735.
   PubMed Web of Science ®Google Scholar
• KIECHL S, WILLEIT J: The natural course of atherosclerosis. Part I. Incidence and progression. Arterioscler. Thromb. Vasc. Biol. (1999) 19:1484-1490.
   PubMed Web of Science ®Google Scholar
• WAXMAN S, ISHIBASHI F, MULLER JE: Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events. Circulation (2006) 114:2390-2411.
   PubMed Web of Science ®Google Scholar
• LAROSA JC, HE J, VUPPUTURI S: Effects of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA (1999) 282:2340-2346.
   PubMed Web of Science ®Google Scholar
• NCEP EXPERT PANEL: Executive summary of the third report of the National cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA (2001) 285:2486-2497.
   PubMed Web of Science ®Google Scholar
• HOCKERMAN GH, PETERSON BZ, JOHNSON BD, CATTERALL WA: Molecular determinants of drug binding and action on L-type calcium channels. Annu. Rev. Pharmacol. Toxicol. (1997) 37:361-396.
   PubMed Web of Science ®Google Scholar
• HAMADA T, WATANABE M, KANEDA T et al.: Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. J. Hypertens. (1998) 16:111-118.
   PubMed Web of Science ®Google Scholar
• WENZEL RR, ALLEGRANZA G, BINGGELI C et al.: Differential activation of cardiac and peripheral sympathetic nervous system by nifedpine: role of pharmacokinetics. J. Am. Coll. Cardiol. (1997) 29:1607-1614.
   PubMed Web of Science ®Google Scholar
• SWANSON DR, BARCLAY BL, WONG PS, THEEUWES F: Nifedipine gastrointestinal therapeutic system. Am. J. Med. (1987) 83(6B):3-9.
   PubMedGoogle Scholar
• BREEKVELDT-POSTMA NS, HERINGS RMC: Persistence with antihypertensives related to formulation: the case of nifedipine. Ann. Pharmacother. (2005) 39(2):237-242.
   PubMed Web of Science ®Google Scholar
• MURDOCH D, BROGDEN RN: Sustained release nifedipine formulations: an appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. Drugs (1991) 41(5):737-779.
   PubMed Web of Science ®Google Scholar
• BROGDEN RN, McTAVISH D: Nifedipine gastrointestinal therapeutic system (GITS): a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Drugs (1995) 50(3):495-512.
   PubMed Web of Science ®Google Scholar
• TING C-T, CHEN J-W, CHANG M-S et al.: Arterial hemodynamics in human hypertension: effects of the calcium channel antagonist nifedipine. Hypertension (1995) 25:1326-1332.
   PubMed Web of Science ®Google Scholar
• BIRKEBAEK NH, GERDES LU, NIELSEN A, FAERGEMAN O, VEJBY-CHRISTENSEN H: Effect of nifedipine and captopril on plasma lipoproteins in hypertensive patients. Curr. Ther. Res. (1989) 46:619-624.
   Web of Science ®Google Scholar
• LEHTONEN A, TANSKANEN A, LEHTO H, JARVENSIVEN F: The effect of nifedipine on plasma lipids in patients with essential hypertension. Int. J. Clin. Pharmacol. Ther. Toxicol. (1986) 24:357-358.
   PubMedGoogle Scholar
• PASANISI F, FERRARA AL, IOVINE C, MANCINI M: Effects of nifedipine on insulin secretion and plasma lipids in hypertensive patients. Curr. Ther. Res. (1986) 39:894-899.
   Web of Science ®Google Scholar
• HOUSTON MC, OLAFSSON L, BURGER MC, LICHTENSTEIN MJ: Effects of nifedipine GITS and atenolol monotherapy on serum lipids in mild to moderate hypertension. Clin. Res. (1990) 38:A542.
   Google Scholar
• KAZUMI T, YOSHINO G, OKUTANI T et al.: Plasma lipoprotein and apolipoprotein concentrations and glycemic control during short-term treatment with nifedipine in hypertensive patients with Type II diabetes mellitus. Curr. Ther. Res. (1989) 46:951-958.
   Web of Science ®Google Scholar
• SASAKI J, ARAKAWA K: Effect of nifedipine on serum lipids, lipoproteins, and apolipoproteins in patients with essential hypertension. Curr. Ther. Res. (1987) 41:845-851.
   Web of Science ®Google Scholar
• GRUNDY JS, FOSTER RT: The nifedipine gastrointestinal therapeutic system (GITS): evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin. Pharmacokinet. (1996) 30(1):28-51.
   PubMed Web of Science ®Google Scholar
• SCHUG BS, BRENDEL E, WONNEMANN M et al.: Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Eur. J. Clin. Pharmacol. (2002) 58(2):119-125.
   PubMed Web of Science ®Google Scholar
• CHUNG M, REITBERG DP, GAFFNEY M, SINGLETON W: Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system: a controlled-release formulation of nifedipine. Am. J. Med. (1987) 83(Suppl. 6B):10-14.
   PubMedGoogle Scholar
• CROOM KF, WELLINGTON K: Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris. Drugs (2006) 66(4):498-528.
   Google Scholar
• NAKAO J, ITO H, OOYAMA T et al.: Calcium dependency of aortic smooth muscle cell migration induced by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid. Atherosclerosis (1983) 46:309-319.
   PubMed Web of Science ®Google Scholar
• NOMOTO A, HIROSUMI J, SEKIGUCHI C et al.: Antiatherogenic activity of FR34235 (nilvadipine) a new potent calcium antagonist. Atherosclerosis (1987) 64:255-261.
   PubMed Web of Science ®Google Scholar
• BETZ E: The effect of calcium antagonists on intimal cell proliferation in atherogenesis. Ann. NY Acad. Sci. (1988) 522:399-410.
   PubMed Web of Science ®Google Scholar
• BETZ E, HAMMERLE H, STROHSCHNEIDER T: Inhibition of smooth muscle cell proliferation and endothelial permeability with flunarizine in vitro and in experimental atheromas. Res. Exp. Med. (1985) 185:325-340.
   PubMedGoogle Scholar
• STROHSCHNEIDER T, BETZ E: Densitometric measurement of increased endothelial permeability in arteriosclerotic plaques and inhibition of permeability under the influence of two calcium antagonists. Atherosclerosis (1989) 75:135-144.
   PubMed Web of Science ®Google Scholar
• HANDLEY DA, VAN VALEN RG, MELDEN MK et al.: Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110. Am. J. Pathol. (1986) 124:88-93.
   PubMed Web of Science ®Google Scholar
• JACKSON LJ, BUSH RC, BOWYER DE: Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion size. Atherosclerosis (1988) 69:115-122.
   PubMed Web of Science ®Google Scholar
• GOTTO AM Jr: Calcium channel blockers and the prevention of atherosclerosis. Am. J. Hypertens. (1990) 3:S342-S346.
   PubMed Web of Science ®Google Scholar
• LICHTOR T: Antiatherosclerotic activity of nifedipine in primates. Cardiovasc. Drug Rev. (1988) 6:339 (Abstract).
   Google Scholar
• SEUTER F: Antiatherosclerotic effects of nifedipine and nitrendipine in rats with experimental atherosclerosis. Cardiovasc. Drug Rev. (1988) 6:337.
   Google Scholar
• THIERY J: The beneficial influence of nifedipine on the regression of cholesterol-induced atherosclerosis in rabbits. Cardiovasc. Drug Rev. (1988) 6:338-339 (Abstract).
   Google Scholar
• HENRY PD, BENTLEY KI: Suppression of atherogenesis in cholesterol-fed rabbits treated with nifedipine. J. Clin. Invest. (1981) 68(5):1366-1369.
   PubMed Web of Science ®Google Scholar
• WILLIS AL, NAGEL B, CHURCHILL V et al.: Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits. Arteriosclerosis (1985) 5(3):250-255.
   PubMedGoogle Scholar
• HAJJAR DP: Role of calcium channel antagonists as antiatherosclerotic agents. Cardiovasc. Drug Rev. (1988) 6:340-341.
   Google Scholar
• BLUMLEIN SL, SIEVERS R, KIDD P et al.: Mechanism of protection from atherosclerosis by verapamil in the cholesterol-fed rabbit. Am. J. Cardiol. (1984) 54:884-889.
   PubMed Web of Science ®Google Scholar
• ROULEAU JL, PARMLEY WW, STEVENS J et al.: Verapamil suppresses atherosclerosis in cholesterol-fed rabbits. J. Am. Coll. Cardiol. (1983) 1:1453-1460.
   PubMed Web of Science ®Google Scholar
• SIEVERS RE, RASHID T, GARRETT J et al.: Verapamil and diet halt progression of atherosclerosis in cholesterol fed rabbits. Cardiovasc. Drugs Ther. (1987) 1:65-69.
   PubMedGoogle Scholar
• GINSBURG R, DAVIS K, BRISTOW MB et al.: Calcium antagonists suppress atherogenesis in aorta but not in the intramural coronary arteries of cholesterol-fed rabbits. Lab. Invest. (1983) 49:154-158.
   PubMed Web of Science ®Google Scholar
• SUGANO M, NAKASHIMA Y, MATSUSHIMA T et al.: Suppression of atherosclerosis in cholesterol-fed rabbits by diltiazem injection. Arteriosclerosis (1986) 6:237-241.
   PubMedGoogle Scholar
• SUGANO M, NAKASHIMA Y, TASAKI H et al.: Effects of diltiazem on suppression and regression of experimental atherosclerosis. Br. J. Exp. Pathol. (1988) 66:515-523.
   Google Scholar
• DAUGHERTY A, RATERI DL: Development of experimental designs for atherosclerosis studies in mice. Methods (2005) 36:129-138.
   PubMed Web of Science ®Google Scholar
• WEINSTEIN DB, HEIDER JG: Antiatherogenic properties of calcium antagonists. Am. J. Cardiol. (1987) 59:B163-B172.
   PubMedGoogle Scholar
• TSCHUDI MR, CRISCIONE L, NOVOSEL D, PFEIFFER K, LUSCHER TF: Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation (1994) 89:2212-2218.
   PubMed Web of Science ®Google Scholar
• HABIB JB, BOSSALLER C, WELLS S, WILLIAMS C, MORRISETT JD, HENRY PD: Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN 200110. Circ. Res. (1986) 58:305-309.
   PubMed Web of Science ®Google Scholar
• GUIDELINES COMMITTEE: 2003 European society of hypertension – European society of cardiology guidelines for the management of arterial hypertension. J. Hypertens. (2003) 21:1011-1153.
   PubMed Web of Science ®Google Scholar
• SIMON A, GARIEPY J, CHIRONI G, MEGNIEN JL, LEVENSON J: Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J. Hypertens. (2002) 20(2):159-169.
   PubMed Web of Science ®Google Scholar
• LICHTLEN PR, HUGENHOLTZ PG, RAFFLENBEUL W et al.; on behalf of the INTACT GROUP INVESTIGATORS: Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet (1990) 335:1109-1113.
   PubMed Web of Science ®Google Scholar
• FLECKENSTEIN A, FREY M, THIMM F, FLECKENSTEIN-GRUM G: Excessive mural calcium overload – a predominant causal factor in the development of stenosing coronary plaques in humans. Cardiovasc. Drugs Ther. (1990) 4(Suppl. 5):1005-1014.
   PubMed Web of Science ®Google Scholar
• SHINODA E, YUI Y, KODAMA K et al.: Comparison of nifedipine retard with angiotensis converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan multicenter investigation for cardiovascular diseases-B (JMIC-B side arm study). The Japan multicenter investigation for cardiovascular diseases-B study group. Hypertension (2005) 45:1153-1158.
   PubMed Web of Science ®Google Scholar
• BROWN MJ, PALMER CR, CASTAIGNE A et al.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet (2000) 356:366-372.
   PubMed Web of Science ®Google Scholar
• SELZER RH, HODIS HN, KWONG-FU H et al.: Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound image. Atherosclerosis (1994) 111:1-11.
   PubMed Web of Science ®Google Scholar
• GRAF S, GARIEPY J, MASSONNEAU M et al.: Experimental and clinical validation of arterial diameter waveform and intimal media thickness obtained from B-mode ultrasound image processing. Ultrasound Med. Biol. (1999) 25:1353-1363.
   PubMed Web of Science ®Google Scholar
• CHOBANIAN AV: 1989 Corcoran lecture: adaptive and maladaptive response of the arterial wall to hypertension. Hypertension (1990) 15:666-674.
   PubMed Web of Science ®Google Scholar
• LAKKA TA, SALONEN R, KAPLAN GA, SALONEN JT: Blood pressure and the progression of carotid atherosclerosis in middle-aged men. Hypertension (1999) 34:51-56.
   PubMed Web of Science ®Google Scholar
• SIMON A, GARIEPY J, MOYSE D, LEVENSON J: Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation (2001) 103:2949-2954.
   PubMed Web of Science ®Google Scholar
• WEINSTEIN DB, HEIDER JG: Antiatherogenic properties of the calcium antagonists. Am. J. Med. (1989) 86(4A):27-32.
   PubMedGoogle Scholar
• HENRY PD: Atherogenesis, calcium and calcium antagonists. Am. J. Cardiol. (1990) 66:31-61.
   PubMed Web of Science ®Google Scholar
• MACARTHY JH, PALMER FJ: Incidence and significance of coronary artery calcification. Br. Heart J. (1974) 36:499-506.
   PubMedGoogle Scholar
• MOTRO M, SHEMESH J: Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension (2001) 37:1410-1413.
   PubMed Web of Science ®Google Scholar
• SIMONS DB, SCHWARTZ RS, EDWARDS WD, SHEEDY PF, RUMBERGER JA: Noninvasive definition of anatomic coronary artery disease by ultrafast computed tomographic scanning: a quantitative pathologic comparison study. J. Am. Coll. Cardiol. (1992) 20:1118-1126.
   PubMed Web of Science ®Google Scholar
• RUMBERGER JA, SIMONS DB, FITZPATRICK LA, SHEEDY PF, SCHWARTZ RS: Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. Circulation (1995) 92:2157-2162.
   PubMed Web of Science ®Google Scholar
• SHEMESH J, STROH CI, TENENBAUM A et al.: Comparison of coronary calcium in stable angina pectoris and in first acute myocardial infarction utilizing double helical computerized tomography. Am. J. Cardiol. (1998) 81:271-275.
   PubMed Web of Science ®Google Scholar
• DEVEREUX RB, ALDERMAN MH: The role of preclinical cardiovascular disease in the evolution from risk factor exposure to the development of clinical morbid events. Circulation (1993) 88:1444-1455.
   PubMed Web of Science ®Google Scholar
• KOREN MJ, DEVEREUX RB, CASALE PN, SAVAGE DD, LARAGH JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med. (1991) 114:345-352.
   PubMed Web of Science ®Google Scholar
• MENSAH GA, PAPPAS TW, KOREN MJ, ULIN RJ, LARAGH JH, DEVEREUX RB: Comparison of classification of hypertension severity by blood pressure level and World health organization criteria for prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. J. Hypertens. (1993) 11:1429-1440.
   PubMed Web of Science ®Google Scholar
• LEVY D, GARRISON RJ, SAVAGE DD, KANNEL WB, CASTELLI WP: Prognostic implications of echocardiographically-determined left ventricular mass in the Framingham heart study. N. Engl. J. Med. (1990) 322:1561-1566.
   PubMed Web of Science ®Google Scholar
• BIKKINA M. LEVY D, EVANS JC et al.: Left ventricular mass and the risk of stroke in an elderly cohort: the Framingham study. JAMA (1994) 272:33-36.
   PubMed Web of Science ®Google Scholar
• GHALI JK, LIAO Y, SIMMONS B, CASTANER A, CAO G, COOPER RS: The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann. Intern. Med. (1992) 117:831-836.
   PubMed Web of Science ®Google Scholar
• BOLOGNESE L, DELLAVESA P, ROSSI L, SARASSO G, BONGO AS, SCIANARO MC: Prognostic value of left ventricular mass in uncomplicated acute myocardial infarction and one-vessel coronary artery disease. Am. J. Cardiol. (1994) 73:1-5.
   PubMed Web of Science ®Google Scholar
• DEVEREUX RB, PALMIERI V, SHARPE N et al.: Effects of once-daily angiotensin-converting enzyme enhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The prospective randomized enalapril study evaluating regression of ventricular enlargement (PRESERVE) trial. Circulation (2001) 104:1248-1254.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, PENNERT K, HANSSON L: Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am. J. Hypertens. (1992) 5:95-110.
   PubMed Web of Science ®Google Scholar
• TADDEI S, VIRDIS A, GHIADONE L et al.: Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension (2001) 37:943-948.
   PubMed Web of Science ®Google Scholar
• THE ENCORE INVESTIGATORS: Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease. The ENCORE I study. Circulation (2003) 107:422-428.
   Google Scholar
• SCHELLEKENS S, VERHEUGT FWA: Hotline sessions of the 26th European congress of cardiology. Eur. Heart J. (2004) 25:2164-2166.
   PubMedGoogle Scholar
• VERHAAR MC, HONING ML, VAN-DAM T et al.: Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc. Res. (1999) 42:752-760.
   PubMed Web of Science ®Google Scholar
• POOLE-WILSON PA, LUBSEN J, KIRWAN B-A et al.: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 364:849-857.
   PubMed Web of Science ®Google Scholar
• LUBSEN J, WAGENER G, KIRWAN B-A et al.: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J. Hypertens. (2005) 23(3):641-648.
   PubMed Web of Science ®Google Scholar
• LUBSEN J, VOKO Z, POOLE-WILSON PA et al.: Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions. J. Clin. Epidemiol. (2007) 60(7):720-726).
   Google Scholar
• EISEN A, TENENBAUM A, KOREN-MORAG N et al.: Coronary and aortic calcifications inter-relationship in stable angina pectoris: a coronary disease trial investigating outcome with nifedipine GITS (ACTION) – Israeli spiral computed tomography substudy. Isr. Med. Assoc. J. (2007) 9:277-280.
   PubMed Web of Science ®Google Scholar
• TOAL CB, MAHON WA, BARNES C et al.: Nifedipine gastrointestinal therapeutic system (GITS) for hypertensive patients in a primary care setting: results of the extended release adalat Canadian trial (EXACT). The EXACT investigators. Clin. Ther. (1997) 19:924-935.
   PubMed Web of Science ®Google Scholar
• BAYER HEALTHCARE: Data on file (2006).
   Google Scholar
• VERHAAR MC, HONING ML, VAN DAM T et al.: Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc. Res. (1999) 42:752-760.
   PubMed Web of Science ®Google Scholar
• National institute of clinical excellence. NICE clinical guideline 18. Management of hypertension in adults in primary care. August (2004).
   Google Scholar
• The National collaborating centre for chronic conditions. Management of hypertension in adults in primary care: partial update. May (2006).
   Google Scholar